Diffuse Cutaneous Systemic Sclerosis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Acquired from Horizon in 2024. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02161406 -
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT04137224 -
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
| Not yet recruiting |
NCT04986605 -
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT02503644 -
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Enrolling by invitation |
NCT05626751 -
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
|
Phase 2 | |
| Withdrawn |
NCT05098145 -
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04478994 -
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1 | |
| Completed |
NCT03198689 -
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Terminated |
NCT04680975 -
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00433186 -
Mycophenolate Mofetil in Systemic Sclerosis
|
Phase 1 | |
| Terminated |
NCT03919799 -
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
| Suspended |
NCT04166552 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06375005 -
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05270668 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
|
Phase 2 | |
| Recruiting |
NCT05168215 -
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
|
||
| Completed |
NCT04440592 -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05149768 -
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
|
Phase 2 | |
| Withdrawn |
NCT04138485 -
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 |